SCHEMBL3291981

SCHEMBL3291981

COCCNc1ncc2c(=O)c(C(N)=O)cn(-c3ccccc3)c2n1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 18/20 0.58
NTRK1 P04629 3/20 0.44
KIT P10721 3/20 0.44
SRC P12931 3/20 0.44
FLT3 P36888 3/20 0.44
PDE4A P27815 1/20 0.44
KCNH2 Q12809 1/20 0.44
AXL P30530 1/20 0.43
TYRO3 Q06418 1/20 0.43
MERTK Q12866 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3293227 0.94 CSF1R (0.56) CSF1RNTRK1KITSRCFLT3
SCHEMBL3293704 0.90 CSF1R (0.53) CSF1RPDE4AKCNH2AXLTYRO3
SCHEMBL3291302 0.88 CSF1R (0.49) CSF1RPDE4AKCNH2AXLTYRO3
SCHEMBL3291400 0.86 CSF1R (0.53) CSF1RNTRK1KITSRCFLT3
SCHEMBL3291712 0.85 CSF1R (0.54) CSF1RKITSRCFLT3PDE4A
SCHEMBL3289880 0.85 CSF1R (0.56) CSF1RNTRK1KITSRCFLT3
SCHEMBL28530641 0.84 CSF1R (0.62) CSF1RPDE4AKCNH2
SCHEMBL3290405 0.84 CSF1R (0.75) CSF1RNTRK1KITSRCFLT3
SCHEMBL3291068 0.83 CSF1R (0.57) CSF1RNTRK1KITSRCFLT3
SCHEMBL3292576 0.83 CSF1R (0.66) CSF1RNTRK1KITSRCFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1945637-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-23 EP claimed
WO-2007033137-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO claimed
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-03-15 US claimed
US-7728003-B2 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-01 US disclosed
EP-1945637-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-23 EP disclosed
WO-2007033137-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR CSF1R 598/4885NTRK1 119/4885KIT 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.